The GLP is committed to full transparency. Download and review our 2019 Annual Report

Viewpoint: France commissions new glyphosate-cancer study to justify more weed killer regulations

| | September 10, 2019
This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.

After reading this article, I relay the following comment from the collective Science-Technologies-Action (STA): “At the request of the [French] government, ANSES is launching a call for applications to improve knowledge on the carcinogenicity of glyphosate.”

This is the title of the communiqué published July 19, 2019 by the four ministers of Agriculture, Health, Research and Ecology who had seized ANSES on March 28, 2018,  “given the divergent opinions offered by the agencies that make reference in the field of evaluation.”

[Editor’s note: Albert Amgar is the former president of a French food safety company.]

The results of this study, costing € 1.2 million [$1,333,092], will be available within 18 months and will complete the review dossier for the re-authorization of glyphosate by the European Union in 2022. The STA Collective is asking several questions about this initiative, including: why do we need a new study on glyphosate when this herbicide has been the subject of nearly 50 years of multiple studies, and all French, European and international health agencies have concluded the absence of health risk?

Related article:  Modern cancer myths and the science behind them

[Editor’s note: This article was written in French. This summary was translated and lightly edited for clarity.]

Read full, original article: Glyphosate: waste of public funds to justify a political decision!

News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.

Send this to a friend